BIOCON | ALEMBIC PHARMA | BIOCON / ALEMBIC PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 31.2 | 16.6 | 187.7% | View Chart |
P/BV | x | 3.7 | 6.6 | 56.3% | View Chart |
Dividend Yield | % | 0.3 | 0.6 | 45.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-19 |
ALEMBIC PHARMA Mar-19 |
BIOCON / ALEMBIC PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 707 | 664 | 106.5% | |
Low | Rs | 554 | 412 | 134.3% | |
Sales per share (Unadj.) | Rs | 91.9 | 208.7 | 44.0% | |
Earnings per share (Unadj.) | Rs | 16.7 | 31.0 | 53.9% | |
Cash flow per share (Unadj.) | Rs | 24.2 | 37.1 | 65.1% | |
Dividends per share (Unadj.) | Rs | 1.00 | 5.50 | 18.2% | |
Dividend yield (eoy) | % | 0.2 | 1.0 | 15.5% | |
Book value per share (Unadj.) | Rs | 101.6 | 144.2 | 70.5% | |
Shares outstanding (eoy) | m | 600.00 | 188.52 | 318.3% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.9 | 2.6 | 266.1% | |
Avg P/E ratio | x | 37.7 | 17.4 | 217.3% | |
P/CF ratio (eoy) | x | 26.1 | 14.5 | 179.9% | |
Price / Book Value ratio | x | 6.2 | 3.7 | 166.3% | |
Dividend payout | % | 6.0 | 17.7 | 33.7% | |
Avg Mkt Cap | Rs m | 378,330 | 101,461 | 372.9% | |
No. of employees | `000 | 6.1 | NA | - | |
Total wages/salary | Rs m | 11,653 | 7,467 | 156.1% | |
Avg. sales/employee | Rs Th | 8,994.3 | NM | - | |
Avg. wages/employee | Rs Th | 1,900.7 | NM | - | |
Avg. net profit/employee | Rs Th | 1,635.3 | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 55,144 | 39,347 | 140.1% | |
Other income | Rs m | 1,444 | 94 | 1,539.4% | |
Total revenues | Rs m | 56,588 | 39,441 | 143.5% | |
Gross profit | Rs m | 15,883 | 8,736 | 181.8% | |
Depreciation | Rs m | 4,478 | 1,152 | 388.6% | |
Interest | Rs m | 709 | 184 | 385.1% | |
Profit before tax | Rs m | 12,140 | 7,493 | 162.0% | |
Minority Interest | Rs m | 9 | 11 | 83.3% | |
Prior Period Items | Rs m | 0 | -93 | 0.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,123 | 1,568 | 135.4% | |
Profit after tax | Rs m | 10,026 | 5,844 | 171.6% | |
Gross profit margin | % | 28.8 | 22.2 | 129.7% | |
Effective tax rate | % | 17.5 | 20.9 | 83.6% | |
Net profit margin | % | 18.2 | 14.9 | 122.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 48,228 | 19,577 | 246.3% | |
Current liabilities | Rs m | 30,376 | 14,896 | 203.9% | |
Net working cap to sales | % | 32.4 | 11.9 | 272.1% | |
Current ratio | x | 1.6 | 1.3 | 120.8% | |
Inventory Days | Days | 68 | 90 | 76.1% | |
Debtors Days | Days | 86 | 45 | 188.5% | |
Net fixed assets | Rs m | 64,130 | 27,097 | 236.7% | |
Share capital | Rs m | 3,000 | 377 | 795.8% | |
"Free" reserves | Rs m | 57,980 | 26,811 | 216.3% | |
Net worth | Rs m | 60,980 | 27,188 | 224.3% | |
Long term debt | Rs m | 15,766 | 4,993 | 315.8% | |
Total assets | Rs m | 121,924 | 47,778 | 255.2% | |
Interest coverage | x | 18.1 | 41.7 | 43.5% | |
Debt to equity ratio | x | 0.3 | 0.2 | 140.8% | |
Sales to assets ratio | x | 0.5 | 0.8 | 54.9% | |
Return on assets | % | 8.8 | 12.6 | 69.8% | |
Return on equity | % | 16.4 | 21.5 | 76.5% | |
Return on capital | % | 16.8 | 23.6 | 71.0% | |
Exports to sales | % | 28.1 | 0 | - | |
Imports to sales | % | 18.9 | 0 | - | |
Exports (fob) | Rs m | 15,506 | NA | - | |
Imports (cif) | Rs m | 10,399 | NA | - | |
Fx inflow | Rs m | 15,506 | 19,453 | 79.7% | |
Fx outflow | Rs m | 10,399 | 6,065 | 171.5% | |
Net fx | Rs m | 5,107 | 13,388 | 38.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,546 | 8,120 | 142.2% | |
From Investments | Rs m | -7,138 | -7,556 | 94.5% | |
From Financial Activity | Rs m | -2,417 | 590 | -409.4% | |
Net Cashflow | Rs m | 2,103 | 1,153 | 182.3% |
Indian Promoters | % | 40.4 | 74.1 | 54.5% | |
Foreign collaborators | % | 20.6 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.4 | 2.9 | 289.7% | |
FIIs | % | 10.7 | 9.1 | 117.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 19.9 | 13.9 | 143.2% | |
Shareholders | 109,995 | 49,328 | 223.0% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: ORCHID PHARMA WYETH ABBOTT INDIA SUVEN LIFE SCIENCES DR. REDDYS LAB
Compare BIOCON With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.
For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More